Engineering of crystalline combination inhalation particles of a long-acting β2-agonist and a corticosteroid

Pharmaceutical Research

Volumn 26, Issue 12, 2009, Pages 2657-2666

  Pitchayajittipong, Chonladda ^a   Shur, Jagdeep ^a   Price, Robert ^a  

^a University of Bath   (United Kingdom)

Author keywords

Combination products; Dry powder inhaler; Glucocorticosteroid; Long acting agonist; SAX

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL;

AEROSOL; ARTICLE; CRYSTALLIZATION; DRY POWDER; PARTICLE SIZE; PHARMACEUTICAL ENGINEERING; POWDER INHALER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; ULTRASOUND; X RAY POWDER DIFFRACTION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG COMBINATIONS; DRUG STORAGE; INHALATION; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS; PROTEIN ENGINEERING;

EID: 70449088928     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-9982-3     Document Type: Article

References (29)

1. PJ Barnes SD Shapiro RA Pauwels 2003 Chronic obstructive pulmonary disease: molecular and cellular mechanisms Eur Respir J 22 672 688 10.1183/09031936.03.00040703 1:CAS:528:DC%2BD3sXovFGgtLY%3D 14582923
2. PJ Barnes 2008 Immunology of asthma and chronic obstructive pulmonary disease Nat Rev Immunol 8 183 192 10.1038/nri2254 1:CAS:528:DC%2BD1cXisVKjsrs%3D 18274560 (Pubitemid 351323287)
3. J Bousquet R Dahk N Khalteev 2007 Global alliance against chronic respiratory diseases Allergy 62 216 223 10.1111/j.1398-9995.2007.01307.x 1:STN:280:DC%2BD2s%2FpvFGnsA%3D%3D 17298337 (Pubitemid 46246495)
4. AP Greening PW Ind M Northfield G Shaw 1994 Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid Lancet 344 219 224 10.1016/S0140-6736(94)92996-3 1:STN:280:DyaK2czgtFSrsw%3D%3D 7913155 (Pubitemid 24229008)
5. J Matz A Emmett K Rickard C Kalberg 2001 Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations J Allergy Clinical Immunol 107 783 789 10.1067/mai.2001.114709 1:CAS:528:DC%2BD3MXktF2rtb8%3D (Pubitemid 32436910)
6. GM Keating PL McCormack 2007 Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease Drugs 67 2383 2406 10.2165/00003495-200767160-00006 1:CAS:528:DC%2BD1cXhvFCrtQ%3D%3D 17983257
7. Baum A, Mann P, Chugbo CC, Nieland N. Morgan Stanley-GlaxoSmithKline. In: 2008. p. 1-13.
8. HS Nelson 2005 Combination therapy of long-acting beta agonists and inhaled corticosteroids in the management of chronic asthma Curr Allergy Asthma Rep 5 123 129 10.1007/s11882-005-0085-x 1:CAS:528:DC%2BD28XlvFGksA%3D%3D 15683612
9. DD Sin SFP Man 2007 Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients? Curr Opin Pulm Med 13 90 97 1:CAS:528:DC%2BD2sXis1yitbw%3D 17255798
10. PJ Barnes 2002 Scientific rationale for inhaled combination therapy with long-acting beta(2)-agonists and corticosteroids Eur Respir J 19 182 191 10.1183/09031936.02.00283202 1:CAS:528:DC%2BD38XhtlGktbo%3D 11843317 (Pubitemid 34105586)
11. HS Nelson KR Chapman SD Pyke M Johnson JN Pritchard 2003 Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers J Allergy Clinical Immunol 112 29 36 10.1067/mai.2003.1558 1:CAS:528:DC%2BD3sXlvVGqsr4%3D (Pubitemid 36819803)
12. Y Michael MJ Snowden BZ Chowdhry IC Ashurst CJ Davies-Cutting T Riley 2001 Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system Int J Pharm 221 165 174 10.1016/S0378-5173(01)00678-0 1:CAS:528:DC%2BD3MXktVGktbY%3D 11397578 (Pubitemid 32524045)
13. A Theophilus A Moore D Prime S Rossomanno B Whitcher H Chrystyn 2006 Co-deposition of salmeterol and fluticasone propionate by a combination inhaler Int J Pharm 313 14 22 10.1016/j.ijpharm.2006.01.018 1:CAS:528: DC%2BD28XjtVGqtb4%3D 16516417
14. M Telko AJ Hickey 2005 Dry powder inhaler formulations Respir Care 50 1209 1227 16122404
15. Braithwaite P, Williams S. Inhaler. US 6,845,772 B2, 2005.
16. R Westmeier H Steckel 2008 Combination particles containing salmeterol xinafoate and fluticasone propionate: formulation and aerodynamic assessment J Pharm Sci 97 2299 2310 10.1002/jps.21154 1:CAS:528:DC%2BD1cXntFWqsrg%3D 17879293
17. H Chiou L Li TT Hu HK Chan JF Chen J Yun 2007 Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation Int J Pharm 331 93 98 10.1016/j.ijpharm.2006.09.022 1:CAS:528:DC%2BD2sXht1GisLY%3D 17052870 (Pubitemid 46176506)
18. JS Kaerger R Price 2004 Processing of spherical crystalline particles via a novel solution atomization and crystallization by sonication (SAXS) technique Pharm Res 21 372 381 10.1023/B:PHAM.0000016252.97296.f1 1:CAS:528: DC%2BD2cXhtlWqsbc%3D 15032321 (Pubitemid 38221985)
19. G Ruecroft 2007 Power ultrasound and particle engineering-crystals for drug delivery and formulation Chemistry Today 25 12 14 1:CAS:528: DC%2BD2sXhtFarsrrN
20. D El-Sabawi R Price S Edge PM Young 2006 Novel temperature controlled surface dissolution of excipient particles for carrier based dry powder inhaler formulations Drug Dev Ind Pharm 32 243 251 10.1080/03639040500466395 1:CAS:528:DC%2BD28XitFChu7k%3D 16537205
21. MD Jones H Harris JC Hooton J Shur GS King CA Mathoulin, et al. 2008 An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances Eur J Pharm Biopharm 69 496 507 10.1016/j.ejpb.2007.11.019 1:CAS:528:DC%2BD1cXmtVSgsr4%3D 18191553
22. M Taki XM Zeng M Oliver C Marriott GP Martin 2006 A comparison of the in-vitro deposition profiles of drugs from a combination dry powder inhaler (DIPI) using the Next Generation Impactor (NGI) J Pharm Pharmacol 58 A65
23. York P, Hanna M. Salmeterol xinafoate with controlled particle size. US 5,795,594 1998.
24. S Beach D Latham C Sidgwick M Hanna P York 1999 Control of the physical form of salmeterol xinofoate Org Process Res Dev 3 370 376 10.1021/op990160z 1:CAS:528:DyaK1MXltVGhtrk%3D
25. HHY Tong BY Shekunov P York AHL Chow 2003 Thermal analysis of trace levels of polymorphic impurity in salmeterol xinafoate samples Pharm Res 20 1423 1429 10.1023/A:1025758127358 1:CAS:528:DC%2BD3sXnt1Kiur4%3D 14567637 (Pubitemid 37164051)
26. D Murnane C Marriott GP Martin 2008 Crystallization and crystallinity of fluticasone propionate Cryst Growth Des 8 2753 2764 10.1021/cg700954t 1:CAS:528:DC%2BD1cXntlKqsLk%3D
27. H Adi D Traini HK Chan PM Young 2008 The influence of drug morphology on the aerosolisation efficiency of dry powder inhaler formulations J Pharm Sci 97 2780 2788 10.1002/jps.21195 1:CAS:528:DC%2BD1cXotF2lsrs%3D
28. MD Ticehurst RC Rowe P York 1994 Determination of the surface-properties of two batches of salbutamol sulfate by inverse gas-chromatography Int J Pharm 111 241 249 10.1016/0378-5173(94)90347-6 1:CAS:528:DyaK2cXmtFarsL0%3D (Pubitemid 24292902)
29. PM Young R Price 2004 The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate Eur J Pharm Sci 22 235 240 10.1016/j.ejps.2004.03.006 1:CAS:528:DC%2BD2cXkvV2ju78%3D 15196579 (Pubitemid 38758010)